Biomedical Innovation

Katie Greene, MPP

Katie is a Research Associate at the Duke-Margolis Center for Health Policy focusing on biomedical innovation, pharmaceutical regulatory science, and opioid policy.  Prior to returning to Duke, Katie served as Senior Policy Advisor and Associate Director of the Office of Intergovernmental and Public Liaison at the White House Office of National Drug Control Policy, where she led the White House’s efforts to build partnerships with state and local governments, advocacy organizations, and public health leaders to reduce opioid abuse and overdose.

Morgan Romine, MPA

Morgan Romine is a Managing Associate at the Duke-Robert J. Margolis, MD, Center for Health Policy in Washington, DC. He currently oversees projects related to biomedical innovation, covering a wide range of issues from drug discovery and development to regulatory review and approval to post-market evidence generation. Before joining the Duke-Margolis Center, Morgan was a Research Associate with the Brookings Institution’s Center for Health Policy and on research staff at the Stowers Institute for Medical Research in Kansas City, Missouri.

Monika Schneider, PhD

Monika Schneider is a Research Associate within the biomedical innovation team at the Duke-Margolis Center for Health Policy. Her work focuses on incentives for antimicrobial product development, value-based reimbursement policy, and payment reform for medical products.

Gabriela Lavezzari, PhD, MBA

Gabriela Lavezzari, PhD, MBA joined the Duke-Robert J. Margolis Center for Health Policy in March 2016. Dr. Lavezzari leads a portfolio of projects aimed at evaluating, creating and implementing new evidence-based policies that shift the current paradigm from fee-for-service (FFS) to value-based reimbursement for innovative medical products. Her primary areas of research interest include medical products payment reform, value-based reimbursement, and economic incentives for antimicrobial medical products.